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Abstract
When people are diagnosed with rare, incurable disorders, they and their families suffer both from the disease itself and from the lack of information and resources
available. They become acutely aware that research can only be conducted when it is funded. This article presents our experiences following the diagnosis of our
daughter with chorea-acanthocytosis, and describes how we established a not-for-profit organization to fund and facilitate research into this rare disease. Personal
relationships with clinicians and scientists, and with friends who were willing to help, have played an essential part in moving the field of neuroacanthocytosis
research forward.
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Introduction
At the age of 24 years, our articulate daughter began to mumble.
Over the next few months occasional, hardly perceptible, involuntary
arm movements developed into sudden, uncontrollable flailing. It slowly
became clear that our daughter was not merely experiencing delayed
adolescent awkwardness. A long trail of medical consultations wound
from primary care to in-hospital observation, and through to the top
neurological specialists. Countless tests and biopsies excluded many
possible diagnoses. Finally, at a Grand Rounds session, a geneticist asked
if our daughter’s blood had been checked for acanthocytes. Acanth-
ocytes were found, and a few days later our daughter was discharged
with a diagnosis of neuroacanthocytosis (NA).1
Searching the web, we found that only a few clinical observations2
had been published since Levine et al. and Critchley et al. first
identified the condition in 1968.3,4 This was not surprising, as the
frequency is estimated to be 1 in 10 million.
Reluctantly, our daughter settled into the safe environment of her
childhood home in London and received excellent care from the
National Health Service. Through sheer chance, we discovered that
research on NA had recently begun at the Wellcome Trust Centre for
Human Genetics at the University of Oxford,5 and that a clinical study
was about to be carried out at the US National Institute of
Neurological Disorders and Stroke by Adrian Danek, MD, who was
undertaking a fellowship there.
What could we, as parents, do? There was no patients’ organization
concerned with the disease, but it was evident that a number of clinicians
and cell biologists were interested. The interest of these professionals was
our motivation. While there was no hope that we could contribute to the
science and, we thought, little chance that we could raise money, there
were some small things we could do. The first step was to translate into
English Dr. Danek’s application (in German) for funding for a proposed
first symposium on NA. The closing of US airports following the events
of September 11, 2001, led to an unexpected visit from American friends
who stayed with us while waiting to return to New York. When they
heard of the proposed symposium they offered to help make it happen,
and we were launched.
The infectious enthusiasm of the professionals at this first
symposium in Germany in 2002 and our own hope of doing
something to help created a ‘‘movement’’ that needed a name:
‘‘Advocacy for Neuroacanthocytosis Patients’’ was born.a Raising
a Advocacy for Neuroacanthocytosis Patients was incorporated and registered as a
charity by the Charity Commission of England and Wales in 2009. Before this, the
charity ‘‘John Grooms’’ handled the Advocacy’s finances.
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$5,000 to fund the publication of a book, Neuroacanthocytosis Syndromes,6
which came out of the first symposium, became our first attempt to ask
friends and neighbors for support. Their response was greater than we
had ever imagined and set us on the road to the next symposium,
another book, and providing modest research grants.
What Can We Do? Roles for Patient Advocacy Groups
Supporting patients and their families
At the heart of our movement are people isolated by an all-
consuming chronic dependency. The clinicians we met initially put a
few affected families in contact with us and our reach slowly widened,
but even after 11 years increased awareness is needed to reach all who
might benefit from mutual support. Most of our contacts still begin
with clinicians suggesting the Advocacy to those patients who are
interested in talking with others who share their position. The internet
and e-mail are invaluable channels for families who need information
and, above all, human contact with others who understand and share
their anxieties, concerns, and hopes. Our active approach to this
‘‘market’’ came from a pioneering publicist friend, Sheila Averbuch,b
who generously offered to create NANews, an e-newsletter reporting on
matters of interest to patients, clinicians, and researchers (available at
www.naadvocacy.org). Circulation has grown to 1,700 subscribers
around the globe. Now in its 20th edition, NANews is available in five
European languages and the search is on for Japanese and Urdu
translators. Our website was created by a friend and was recently
upgraded and expanded with the help of a professional consultant. A
dedicated section of the website allows patients to write about their
experiences with NA and exchange correspondence in a safe,
monitored environment.7 Translations into five European languages
are also available. These translations are provided by the RareConnect
service of the National Organization for Rare Diseases and
EURORDIS, the European rare disease advocacy group. In addition,
many of the language obstacles are overcome with French-, German-,
Portuguese-, and Spanish-speaking ‘‘patient advocates,’’ who respond
to e-mails from patients and families and support translation of the
newsletter.
Diagnostic support and personal contacts have brought to light
many new patients with NA, increasing the estimated number of
people with this condition from 500 to 1,000 worldwide (A. Danek,
personal communication).
Providing resources for clinicians
Even the most experienced neurologists in world centers of
excellence are unlikely to see more than a few NA patients over their
entire careers. Thus, a major responsibility for our patient advocacy
group is to support opportunities for professionals to learn about NA
and provide help with diagnosis, clinical experience, and patient
support.
Dedicated medical professionals are vital contributors to this
education initiative. One role of the Advocacy is to support symposia
that are partly devoted to the clinical aspects of NA. Such meetings
have been held in Munich, Montreal, Kyoto, London, Bethesda (MD,
USA) and Ede. The publication of two books and several journal
review articles based on contributions from speakers at our symposia
provide an academic resource.6,8 This resource is brought to life when
‘‘our’’ professionals are invited to speak at meetings of neurologists
who are especially concerned with Huntington’s and Parkinson’s
diseases. The book The Differential Diagnosis of Chorea,9 edited by our
colleague Ruth H. Walker, provides a framework for the neurologist
observing undiagnosed chorea.
A free diagnostic service is offered by Ludwig-Maximilians
Universita¨t in Munich, with support from the Advocacy.10 The test
uses an antibody against VPS13A (vacuolar protein sorting 13
homolog A; also known as chorein), identified by researchers from
the Wellcome Trust Centre for Human Genetics.11 Absence of
VPS13A indicates chorea-acanthocytosis (ChAc). If the protein is
present then colleagues at University Hospital, Zurich, can determine
if the Kx antibody is missing, indicating a diagnosis of McLeod
syndrome (MLS).12
To facilitate clinical research and potentially collect pathologic
samples, we have supported Ludwig-Maximilians Universita¨t in
collecting uniform, descriptive reports in a patient registry, hosted by
the European Huntington’s Disease Network platform.c The VPS13A
Western blot diagnostic service was planned to be a source of new
entries into the Patient Registry, offered free of charge with the request
that the requesting physician enter the patient’s information into the
anonymized database.13
Together with clinicians, the Advocacy encourages patients and
their families to consider post-mortem tissue donation for research. When
necessary, the Advocacy funds autopsies or transportation of samples
to the tissue bank.
Basic scientific research
Prior to the first NA symposium in 2002, fundamental genetic
studies had linked MLS to the causative XK gene14 and Levine–
Critchley disease, renamed ChAc, to VPS13A. These studies were
performed at the Wellcome Trust Centre for Human Genetics, and
their findings were soon independently confirmed by researchers at
Kagoshima University.15
ChAc and MLS are both associated with degeneration of the basal
ganglia. In addition to the similar movement disorders seen in both,
they share two further common characteristics: 1) acanthocytosis
(thorn-like membranes of red blood cells); and 2) absence of the
expression of specific proteins (VPS13A for ChAc and Kx for MLS).
An initiative to study acanthocytes for clues regarding the pathway
to neurodegeneration was proposed by Ruth Walker and Giel Bosman
b Sheila McDonald Averbuch is a Harvard and Stanford-trained journalist who, with
her husband, Ralph, created ENNclick, a content service focussed on the use of social
media.
c The European Huntington’s Disease Network and the CHDI Foundation are
exemplary organizations pursuing the welfare of patients with Huntington’s disease
and research focussed on therapies for Huntington’s disease. We are grateful to
Professor Bernard Landwehrmeyer for his support of patients with NA.
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in 2003. Starting with a small grant of $10,000, this project continues
with direct grants from the Advocacy and substantial grants from the
E-RARE program.d
In 2006, a commitment of $250,000 from a concerned donor
provided the Advocacy with the resources for a planned research
program. We learned a powerful lesson regarding the need for
business-like management of grants following the funding of a project
for a mouse model of ChAc that went unfulfilled. Thus, we set about
looking to create an independent, outward-looking process that could
objectively analyze grant applications. We needed experts in the basic
cell biology of neurodegeneration as it related to the characteristics of
NA diseases. Fortunately, introductions from another well-connected
friend led us to form an independent and expert scientific panel.
In 2007, we issued our first call for research proposals. The
application format was contributed by the Huntington’s Disease
Society of America and, with permission, we adopted the ‘‘Conditions
on which a grant is awarded’’ of the Wellcome Trust. An important
added condition was the requirement for a short twice-yearly progress
report, suitable for lay people, to be published in NANews.
One successful application was for a grant to study the significance
of the loss of VPS13A expression in ChAc, which grew out of the 2008
symposium in London and Oxford. The aims of the study included:
N Identifying the activity of homolog proteins in a yeast model.
N Creating and studying induced pluripotent stem cell neurons from
ChAc patients, in search of the cause of and eventual therapy for
NA diseases.
N Developing specific antibodies against VPS13A. These antibodies
are essential for visualizing VPS13A in cells and tissue extractions,
and to facilitate studies of cell biology and animal models.
To date, the Advocacy has invested $544,000 in six research
projects. This seed money has stimulated collaboration and interest,
culminating in the creation of the European Multidisciplinary
Initiative on Neuroacanthocytosis (EMINA), which in 2009 won a
grant under the European Union’s E-RARE program. In 2012 a
second grant, for EMINA II, was successfully funded, and is
supporting expanded studies of acanthocytes, molecular pathways in
ChAc neurons generated from induced pluripotent stem cells from
patients and controls, characterization of animal models of ChAc, and
dissecting biochemical changes to ChAc neuronal networks.
These grants have added up to $1,756,000 in research funding, and
other recipients of Advocacy grants have been encouraged to apply for
further funding from the National Institutes of Health.
Further roles and opportunities for our contributions
Our success in recruiting growing numbers of scientists dedicated to
the understanding of NA has brought with it the challenge of facilitating
and building collaboration between geographically diverse research
efforts. Different teams will invariably observe different phenomena, and
the Advocacy seeks to encourage and support the collegial spirit that has
been a hallmark of the NA movement over the past 15 years.
Working with our professional colleagues, the Advocacy now aims
to expand interest in the pathological pathway of degeneration of the
basal ganglia, for example by finding new cell biology researchers to
deepen the investigations into autophagy. In addition, the Advocacy is
preparing for the time when understandings won by academic
scientists can form the basis of collaboration with pharmaceutical
and biotechnology companies in developing potentially therapeutic
molecules, leading to trials and ultimately a therapy. Friends have
introduced us to companies such as GlaxoSmithKline, Novartis,
Boehringer Ingelheim, and Alexion. In addition to potential future
collaborations on therapies, some of these companies have also
supported our educational role. As academic research leads to a
greater understanding of the pathologic processes involved in NA,
collaborations with industry will make an important contribution to
our ultimate goal of finding a cure.
Such a rare and dispersed disease presents practical challenges to
research. For example, there are only a few tissue donors in any one
country. Supplying tissue samples across borders is hampered by a lack
of contacts and by national regulations regarding the use of human
tissue for research. These are practical problems that support from the
Advocacy can overcome. The Advocacy should continue to play a role
in coordinating the supply of blood samples and patient information
for research.
Another important role of the Advocacy, providing a conduit
between patients and its professional partners, is that of supporting
pharmacovigilance. Patient reports of both beneficial and harmful
drug reactions will be encouraged and passed to the appropriate
authorities.
The internet and e-mail have been crucial assets in supporting the
widely spread patient group and developing the international research
effort. While e-mail is convenient for most of the older generations, it may
be replaced by other forms of social media, which resemble sensitive ears
listening in on conversations and deciding which to follow. Many people
do not regularly review either websites or patient-message exchanges
such as RareConnect. Learning to use wider social media for the benefit
of patients, patients’ families, and professionals is a new challenge.
The progress made in the field of NA since 2001 has only been
possible because of the generosity of donors and the voluntary
contributions of medical professionals, families and friends of the
Advocacy, and a myriad of volunteers. Important challenges include
finding ways of continuing with this and identifying new leaders as the
inevitable passing of leadership occurs.
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